Navigation Links
Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/18/2009

/li>

"We remain focused on our goal of filing an Investigational New Drug Application for SNS-01 before the end of calendar year 2009," said Bruce Galton, President and CEO of Senesco. "The recently announced results of the maximum tolerated dose, preclinical toxicology, and efficacy / dose range finding studies for SNS-01 was an important step toward accomplishing this goal."

The Company did not record any revenue for the three month period ended December 31, 2008. Total revenues of $6,250 for the three month period ended December 31, 2007 consisted of the amortized portion of previous milestone payments received in connection with certain agricultural license agreements.

Research and development expenses during the three month period ended December 31, 2008 were $579,286, compared with $392,254 during the three month period ended December 31, 2007, an increase of 47.7%. This increase was primarily a result of an expansion of Senesco's human health programs, specifically the Company's multiple myeloma research program, which was partially offset by a decrease in agricultural research expenses as a result of a decrease in the allocation of resources from agriculture to human health at the University of Waterloo.

General and administrative expenses were $649,056 for the three month period ended December 31, 2008, compared with $585,851 during the three month period ended December 31, 2007, an increase of 10.8%. This increase was primarily due to a $64,000 increase in stock based compensation, an approximately $21,000 increase in professional fees, which were the result of an increase in legal fees, and an approximately $16,000 increase in director fees, which were due to the Company implementing a cash compensation plan for non-employee directors beginning July 1, 2008.

At December 31, 2008, Senesco had cash, cash equivalents and investments of $3,615,
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
2. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
3. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
5. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
6. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
7. Senesco Technologies to Present at BIO 2008 Business Forum
8. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... a leading clinical stage biotechnology company with offices ... proprietary stem cell and tissue engineering based therapies, ... Cooperative Research and Development Agreement (CRADA) with the ... at Fort Sam Houston, Texas. The 3-year CRADA, ...
... PARK, Md., June 6, 2011 CosmosID™, a ... (TAP) incubator developing comprehensive pathogen identification technologies, ... life sciences company category during the 2011 Maryland ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) In ...
... June 6, 2011 Celtaxsys, Inc., a private biopharmaceutical company ... sciences industry veteran, H. Daniel Perez, M.D., to its Board ... Dr. Perez has joined the Celtaxsys team," says Dr. Michael ... "He brings more than 25 years of high level pharmaceutical ...
Cached Biology Technology:Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 2Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 2Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 4Dr. H. Daniel Perez Joins Celtaxsys Board of Directors 2
(Date:7/10/2014)... 10 July 2014 Amyloid diseases, such as ... spongiform encephalopathies, all share the common trait that ... plaques. Yet in vitro studies have found that ... themselves are very toxic. New evidence using two-dimensional ... structure during the amylin aggregation pathway that may ...
(Date:7/10/2014)... 10,2014 For children and teens living with a ... contribute to decreased quality of life, reports a study ... Behavioral Pediatrics , the official journal of the ... The journal is published by Lippincott Williams & ... . , "Self-competence may function as a protective factor ...
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2For children with pacemakers, 'self-competence' affects quality of life 2
... appointment of Esin Gulari, dean of the College of Engineering ... Science Board (NSB). President George W. Bush nominated Gulari for ... is a tremendous honor for me as a scientist and ... in a unique position to make contributions on a national ...
... 3, 2008 Case Western Reserve University School of Medicine ... The National Children,s Study, the National Institutes of Health,s comprehensive ... children,s health. At a briefing today, NIH ... one of 36 new and existing study centers which would ...
... observance of Nuclear Medicine Week (October 5 to 11) ... today a new fact sheet highlighting recent developments in ... in which breast cancer is diagnosed and treated. ... painless imaging tool for diagnosing and treating breast cancer. ...
Cached Biology News:US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board 2NIH selects Case Western Reserve University to participate in National Children's Study 2SNM releases new fact sheet on breast cancer and molecular imaging 2
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Rad51B...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: